TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04335461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cephalomedullary nailing of extracapsular hip fracture
Description: All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cephalomedullary nailing of extracapsular hip fracture
Description: All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cephalomedullary nailing of extracapsular hip fracture
Description: All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cephalomedullary nail
Description: Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cephalomedullary nail
Description: Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cephalomedullary nail
Description: Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional Anesthetics
Description: Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional Anesthetics
Description: Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
Study: NCT06406426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
Description: Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
Description: Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
Study: NCT06144567

Intervention type: DRUG
Intervention: Upadacitinib
Description: As this is an observational study, AbbVie is not involved in the product supply since the drug is being used according to the approved marketing label and is to be prescribed by the physician under usual and customary practice of physician prescription.
Study: NCT05129683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebellar stimulation group
Description: Single-session atDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively Xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins will also be given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal tDCS cerebral (M1) stimulation group
Description: single session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: single session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
Study: NCT05476757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169
Description: rDEN2Δ30-7169 will be inoculated at Study Day 0. After 6 months of the inoculation, the participants will be vaccinated with Dengvaxia® until completion of 3 doses with 6-month interval between each dose.
Study: NCT05588713

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brief assessment protocol
Description: The intervention constitutes of a brief assessment protocol for assessing ADHD.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Comprehensive assessment protocol
Description: The intervention constitutes of a comprehensive assessment protocol for assessing ADHD.
Study: NCT04464473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
Study: NCT05546112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Trigeminal Electrical Nerve Stimulation using YPS-401B
Description: A device that improves insomnia symptoms by transcutaneously applying electrical stimulation including a pulse (10 kHz) burst waveform (10 Hz) to the forehead area to the trigeminal nerve

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation using YPS-401B
Description: A device that is attached in the same way as a real medical device, but actually applies a shum stimulus
Study: NCT06634342

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV RNA Rapid testing
Description: Participants will receive point-of-care hepatitis C RNA testing using the GeneXpert IV Xpress System technology.
Study: NCT06030986

Intervention type: DIAGNOSTIC_TEST
Intervention: ILCOR Utstein OHCA Core Outcome
Description: ILCOR Utstein OHCA Core Outcome

Intervention type: DIAGNOSTIC_TEST
Intervention: ILCOR Utstein OHCA Core Outcome
Description: ILCOR Utstein OHCA Core Outcome
Study: NCT06000813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH-Es
Description: REACH-Español is a mobile health platform adapted from the original REACH intervention to a Latino population with type 2 diabetes. The goal of REACH-Español is to improve diabetes medication adherence and glycemic management in this population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
Study: NCT05572671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laboratory task modeling smoking lapse behavior
Description: Participants will complete a task (the behavioral intervention) designed to model smoking lapse behavior in the laboratory; during the task, they will be given the option of delaying smoking in exchange for monetary reinforcement.
Study: NCT03729817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Submaximal balloon angioplasty
Description: An endovascular procedure involving inflation of a balloon catheter undersized to 50-75% of normal vessel diameter to perform angioplasty of a stenotic blood vessel segment, with the goal of increasing blood flow.
Study: NCT05777577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic therapy
Description: probiotic including bifidobacterium
Study: NCT05149859

Intervention type: OTHER
Intervention: Observational
Description: (no intervention)

Intervention type: OTHER
Intervention: Observational
Description: (no intervention)
Study: NCT04943276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embr Device
Description: The Embr thermal device will be worn at all times from study start to the study endpoint.
Study: NCT04325204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-based Home Activity Toolbox (Faith-HAT)
Description: They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-based Home Activity Toolbox (Faith-HAT)
Description: They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project.
Study: NCT05703269

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: single fraction stereotactic radiosurgery (SSRS)
Description: SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fractionated stereotactic radiosurgery (FSRS)
Description: FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
Study: NCT05076695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: Pyrotinib 400mg, PO daily, continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
Study: NCT05403255

Intervention type: OTHER
Intervention: evaluation of the quality of life with questionnaires
Description: Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France.
Study: NCT05390801

Intervention type: OTHER
Intervention: Survey
Description: Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
Study: NCT06017479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin 3000 MG
Description: Fosfomycin 3 g single dosage 1 hour before the urodynamic examination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
Study: NCT05341349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Undergo TTFields

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Undergo TTFields
Study: NCT06433024

Intervention type: DIAGNOSTIC_TEST
Intervention: PPG Diagnostic
Description: The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
Study: NCT05777577

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic therapy
Description: probiotic including bifidobacterium
Study: NCT06149741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Defunctioning left-sided loop colostomy
Description: Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
Study: NCT04177004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT04747236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Azacytidine, 300 mg po daily on Days 1-14
Study: NCT05433792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myolens CN (Central-Near) soft contact lens
Description: Personal fitting of the Myolens-CN/CF.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myolens CN (Central-Near) soft contact lens
Description: Personal fitting of the Myolens-CN/CF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiSight® soft contact lens
Description: Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
Study: NCT05144360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenas
Description: ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenas placebo
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
Study: NCT06281106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deucravacitinib
Description: Daily drug intake for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Daily drug intake for 4 weeks.
Study: NCT05969262

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics technology and liquid biopsy
Description: using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
Study: NCT05612789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program (Cohort A Prehab)
Description: Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program (Cohort B Rehab)
Description: All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
Study: NCT04908878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block
Description: Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane (SAP) block
Description: Patients will receive US-guided SAP block after induction of general anesthesia.
Study: NCT05132920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
Study: NCT04925362

Intervention type: OTHER
Group type: OTHER
Intervention: Biological specimens
Description: Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)

Intervention type: OTHER
Group type: OTHER
Intervention: Additional visit
Description: Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
Study: NCT05385731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking (NWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Walking (FWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Walking (FWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HEG)
Description: The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education (HEG)
Description: The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months.
Study: NCT06177327

Intervention type: OTHER
Intervention: Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.
Description: Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
Study: NCT05175898

Intervention type: DEVICE
Intervention: VA-ECMO
Description: Treatment with veno-arterial extracorporeal membrane oxygenation

Intervention type: DEVICE
Intervention: ECMELLA
Description: Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
Study: NCT05461313

Intervention type: OTHER
Group type: OTHER
Intervention: Constrained Liner
Description: Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)

Intervention type: OTHER
Group type: OTHER
Intervention: Dual Mobility
Description: Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
Study: NCT05051982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedline EEG in View
Description: EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
Study: NCT05939076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
Description: Antiarrhythmic drugs
Study: NCT05931510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofscual release
Description: I will apply myofascial release on group A patients and observse its effects on shin splint

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxation.
Description: I will apply post isonetric relaxation on group b patients and observe effects on shin splint